Breast cancer online : BCO最新文献

{"title":"Anti-angiogenic therapy: from laboratory to the patient","authors":"F. Ademuyiwa, G. Sledge","doi":"10.1017/S1470903109990186","DOIUrl":"https://doi.org/10.1017/S1470903109990186","url":null,"abstract":"Angiogenesis, or new vessel formation, plays a key role in the process of tumor growth and metastasis in breast cancer. Recent large phase-III trials (E2100 and AVADO) demonstrate the clinical utility of bevacizumab in combination with front-line taxane-based chemotherapy in patients with metastatic breast cancer, leading to its recent approval in the United States and Europe. Several other anti-angiogenic strategies against vascular endothelial growth factor are in various phases of clinical development. This paper reviews the data on bevacizumab in metastatic breast cancer and other anti-angiogenic strategies on development in breast cancer.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delivering bad news: a vital skill for professionals involved in breast cancer care","authors":"M. Linver","doi":"10.1017/S1470903109990174","DOIUrl":"https://doi.org/10.1017/S1470903109990174","url":null,"abstract":"Delivering bad news to patients being evaluated for and diagnosed with breast cancer requires a unique blend of medical knowledge, compassion, and sensitivity. Although many of the techniques involved are intuitive, one can enhance these skills by incorporating a few simple concepts into the patient encounter. By combining these with an understanding of appropriate responses to possible patient reactions to the news, one can create a more effective groundwork for the patient’s recovery on both physical and emotional levels.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Phyllodes tumor of the breast with sarcomatous degeneration","authors":"A. Aizer, W. Polkinghorn, C. Wynveen, L. Montgomery, B. McCormick","doi":"10.1017/S1470903109990150","DOIUrl":"https://doi.org/10.1017/S1470903109990150","url":null,"abstract":"","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990150","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of the intact breast primary in the setting of metastatic disease","authors":"H. Bermas, S. Khan","doi":"10.1017/S1470903109990162","DOIUrl":"https://doi.org/10.1017/S1470903109990162","url":null,"abstract":"Women who present with new breast cancer and synchronous metastases have traditionally been treated with systemic agents, with no specific therapy for the primary tumor unless local symptoms require palliation. However, a number of retrospective analyses of survival outcomes in these patients show that surgery for the primary tumor is associated with prolongation of survival. These studies suggest the possibility that local therapy for the primary tumor provides value beyond palliation of symptoms and points to the need for prospective data to guide treatment plans for women with de novo metastatic breast cancer. The coherence of the available data is improved by the findings that surgical resection of the primary tumor is of value only when free surgical resection margins are achieved, and that maintenance of local control at the primary site is associated with a survival advantage. Nevertheless, many questions remain, including the optimal timing of surgery for the primary tumor, whether the potential benefit applies only to women with favorable metastatic sites (e.g. bone-only metastases), and whether local radiotherapy should follow surgical treatment of the primary tumor if this is elected. There is also a lack of data addressing the value of axillary surgery in the metastatic setting. These substantial knowledge gaps limit our ability to deploy optimal use of therapeutic modalities for a patient population that reaches large numbers world-wide, and among whom survival duration is increasing due to more effective systemic therapy.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903109990162","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin-, nipple-, and areola-sparing mastectomy","authors":"E. Umoh, N. Arora, R. Simmons","doi":"10.1017/S1470903108007682","DOIUrl":"https://doi.org/10.1017/S1470903108007682","url":null,"abstract":"Surgical management of breast carcinoma has evolved to include more breast conserving techniques such as skin-, nipple-, and areola-sparing mastectomies, as improved cosmesis becomes an increasing concern. However, the oncologic risk of these procedures must be strongly considered before such techniques can be widely adopted. Here we review available literature on these techniques and their associated clinical outcome. From our own experience, as well as from that reported, we conclude that nipple-, skin-, and areola-sparing mastectomies in carefully selected patients can have safe oncologic outcomes comparable to more traditional surgical techniques and therefore may be a feasible option for breast cancer management.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108007682","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of: Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen","authors":"S. Loi","doi":"10.1017/S1470903108008407","DOIUrl":"https://doi.org/10.1017/S1470903108008407","url":null,"abstract":"Citation of original article:Koket al.Breast Cancer Research and Treatment4 March 2008 [Epub ahead of print].Abstract of the original article:Background:Molecular signatures that predict outcome in tamoxifen-treated breast cancer patients have been identified. For the first time, we compared these response profiles in an independent cohort of (neo)adjuvant systemic treatment naive breast cancer patients treated with first-line tamoxifen for metastatic disease.Methods:From a consecutive series of 246 estrogen receptor (ER) positive primary tumors, gene expression profiling was performed on available frozen tumors using 44K oligoarrays (n= 69). A 78-gene tamoxifen response profile (formerly consisting of 81 cDNA clones), a 21-gene set (microarray-based Recurrence Score), as well as the HOXB13-IL17BR ratio (Two-Gene Index, RT-PCR) were analyzed. Performance of signatures in relation to time to progression (TTP) was compared with standard immunohistochemical (IHC) markers: ER, progesterone receptor (PgR) and HER-2.Results:In univariate analyses, the 78-gene tamoxifen response profile, the 21-gene set and the HOXB13-IL17BR ratio were all significantly associated with TTP with hazard ratios of 2.2 (95% CI 1.3–3.7,P= 0.005), 2.3 (95% CI 1.3–4.0,P= 0.003) and 4.2 (95% CI 1.4–12.3,P= 0.009), respectively. The concordance among the three classifiers was relatively low, they classified only 45–61% of patients in the same category. In multivariate analyses, the association remained significant for the 78-gene profile and the 21-gene set after adjusting for ER and PgR.Conclusion:The 78-gene tamoxifen response profile, the 21-gene set and the HOXB13–IL17BR ratio were all significantly associated with TTP in an independent patient series treated with tamoxifen. The addition of multigene assays to ER (IHC) improves the prediction of outcome in tamoxifen-treated patients and deserves incorporation in future clinical studies.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008407","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The sexuality clinic in the breast center: sex as a survivorship issue","authors":"D. Dizon, D. Thompson, C. Duffy, D. Wiggins","doi":"10.1017/S147090310800802X","DOIUrl":"https://doi.org/10.1017/S147090310800802X","url":null,"abstract":"Breast cancer and its treatments can cause sexual dysfunction in up to 90% of women with the disease. Front line care providers often do not have the time or training to focus on this quality of life issue and the private nature of the topic can prevent women from pursuing help. By setting up a clinic specifically devoted to sexuality issues, breast cancer treatment centers can provide a place to address these issues and help patients deal with the after-effects of their treatment. As breast cancer survivor rates and disease-free intervals increase, the demand for a service that supports women returning to as near-normal a life as possible will only grow.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S147090310800802X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant chemotherapy for older women with breast cancer","authors":"H. Muss","doi":"10.1017/S1470903108006457","DOIUrl":"https://doi.org/10.1017/S1470903108006457","url":null,"abstract":"Many older women today with early-stage breast cancer have estimated survivals exceeding 5–10 years at the time of diagnosis and should be considered for systemic adjuvant chemotherapy. When available and if eligible, such patients should be offered clinical trials participation. Given the median age for onset of breast cancer, trials should also be developed to specifically investigate the disease in this age group. Oncologists caring for elders need to educate their colleagues as well as their patients concerning the pitfalls of age bias and the potential hazard of under-treatment and poorer outcomes.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108006457","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Male breast cancer after heart transplantation: a Case Study from The University of California, San Francisco","authors":"J. Zakhireh, J. Park, D. McGlothlin, L. Esserman","doi":"10.1017/S1470903108008225","DOIUrl":"https://doi.org/10.1017/S1470903108008225","url":null,"abstract":"","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008225","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic science: (July 2008)","authors":"R. Sutherland","doi":"10.1017/S1470903108008377","DOIUrl":"https://doi.org/10.1017/S1470903108008377","url":null,"abstract":"1. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 2008; 99: 404–407. 2. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang YX, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324–3330. 3. Barnett GC, Shah M, Redman K, Easton DF, Ponder BAJ, Pharoah PDP. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008; 26: 3310–3316. 4. Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimaki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A. Tissue-specific promoters active in CD44(1)CD24(2/low) breast cancer cells. Cancer Res 2008; 68: 5533–5539. 5. Belkhiri A, Dar AA, Peng D, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res 2008; 14: 4564–4571. 6. Crandall CJ, Guan M, Laughlin GA, Ursin GA, Stanczyk FZ, Ingles SA, Barrett-Connor E, Greendale GA. Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 2008; 17: 1674–1681. 7. Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, DeFreese DC, Gramling BA, Evans I, White E. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 1751–1759. 8. Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D, Reis-Filho JS, Ellis IO. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008; 99: 327–334. 9. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomakii K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H: quinone oxidoreductase 1 NQO1(star)2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008; 40: 844–853. 10. Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene 2008; 27: 4075–4085. 11. Gail MH. Discriminatory accuracy from singlenucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037–1041. 12. Ghoussaini M, Song HL, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus SJ, Kjaer SK, Hogdall E, D","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}